<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753792</url>
  </required_header>
  <id_info>
    <org_study_id>CORTEM</org_study_id>
    <secondary_id>2007-000888-15</secondary_id>
    <nct_id>NCT00753792</nct_id>
  </id_info>
  <brief_title>Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During Relapse</brief_title>
  <official_title>Multicenter, Randomized, Double Blind, Clinical Trial to Compare the Clinical and Radiological Efficacy of Equivalent Doses of Methylprednisolone Administered Orally or Intravenously in Patients With Multiple Sclerosis During Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IV, multicenter, randomized, double blind clinical trial. The investigators&#xD;
      will study 48 patients with remitting relapsing multiple sclerosis (MS) experiencing moderate&#xD;
      or severe attack receiving immunomodulatory therapy or not. Patients will be randomly&#xD;
      assigned to one of the two groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double blind clinical trial to test whether oral&#xD;
      methylprednisolone (MP) is not inferior to intravenous methylprednisolone for the treatment&#xD;
      of multiple sclerosis (MS) relapse in terms of clinical and radiological efficacy.&#xD;
&#xD;
      Patients will be randomly assigned to one of the following two groups.&#xD;
&#xD;
      Group A: methylprednisolone 1.000 mg/day intravenous administered during three days + placebo&#xD;
      of methylprednisolone orally administered&#xD;
&#xD;
      Group B: methylprednisolone 1.250 mg/day orally administered during three days + placebo of&#xD;
      methylprednisolone intravenously administered.&#xD;
&#xD;
      Clinical visits will be conducted at 7, 28 and 90 days after treatment starting.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the punctuation of diana functional system score corresponding to in relapse of optic neuritis, trunk's syndrome and myelitis</measure>
    <time_frame>day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in EDSS in patients who present a relapse from different type or unknown topography</measure>
    <time_frame>day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the punctuation in each group</measure>
    <time_frame>between days 7 and 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who improve, get worse and keep stable</measure>
    <time_frame>days 7 and 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>methylprednisolone 1.000 mg/day intravenous administration during three days + placebo of methylprednisolone orally administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>methylprednisolone 1.250 mg/day orally administered during three days + placebo of methylprednisolone intravenous administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>methylprednisolone 1.000 mg/day intravenous administration during three days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Group A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>methylprednisolone 1.250 mg/day orally administered during three days</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Group B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of methylprednisolone administered intravenously (Arm 2) or orally (Arm 1)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Group A</other_name>
    <other_name>Group B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. To have been diagnosed MS Remittent Recurrent according to Mc Donald 20052 criteria.&#xD;
&#xD;
          2. To have an EDSS between 0 and 5 before the relapse.&#xD;
&#xD;
          3. The symptoms have begun after at least one month of previous stability.&#xD;
&#xD;
          4. The symptoms have started maximum 15 days before the inclusion.&#xD;
&#xD;
          5. The patient is capable of having an adequate communication with the investigator and&#xD;
             to carry out with the clinical trial requisites.&#xD;
&#xD;
          6. To be or not to be with allowed immunomodulatory therapy (IFN-B /AG).&#xD;
&#xD;
          7. To be capable and to be willing to ingest the medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. First inflammatory neurological episode (relapse).&#xD;
&#xD;
          2. Multiple sclerosis secondary progressive or primary progressive.&#xD;
&#xD;
          3. The symptoms have gone on for less than 24 hours.&#xD;
&#xD;
          4. To be in treatment or have been treated with corticoids during the three months&#xD;
             before.&#xD;
&#xD;
          5. Patients in treatment with immunosuppressors (azathioprine, mitoxantrone,&#xD;
             ciclofosfamide...)&#xD;
&#xD;
          6. Pregnancy or breastfeeding or women in fertile age who don't use contraceptives&#xD;
             measurements.&#xD;
&#xD;
          7. Illnesses with contraindication treatment with corticoids.&#xD;
&#xD;
          8. Antecedents of serious adverse effects or hypersensitive to related study medication.&#xD;
&#xD;
          9. Patients who wouldn´t be able to perform periodic RMN explorations, patients who are&#xD;
             not collaborative or who need anesthesia.&#xD;
&#xD;
         10. Patients with intolerance to lactose.&#xD;
&#xD;
         11. Patients with allergy to contrast used in RMN.&#xD;
&#xD;
         12. Patients with chronic kidney disease.&#xD;
&#xD;
         13. Patients in treatment with natalizumab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cristina Ramo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Germans Trias i Pujol Hospital</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Figueres</name>
      <address>
        <city>Figueres</city>
        <state>Girona</state>
        <zip>17600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Mataró</name>
      <address>
        <city>Barcelona</city>
        <zip>08034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Trueta</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>September 16, 2008</study_first_submitted>
  <study_first_submitted_qc>September 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2008</study_first_posted>
  <last_update_submitted>June 1, 2011</last_update_submitted>
  <last_update_submitted_qc>June 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Cristina Ramo. MD</name_title>
    <organization>Germans Trias i Pujol University Hospital</organization>
  </responsible_party>
  <keyword>multiple sclerosis</keyword>
  <keyword>relapse</keyword>
  <keyword>methylprednisolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

